 |
4 Diseases |  |
0 Trials |
|
0 Trials |  |
21 News |  |
- || Review, Journal: Toward the Eradication of Herpes Simplex Virus: Vaccination and Beyond. (Pubmed Central) - Sep 29, 2024
However, GEN-003 and HerpV have not advanced further despite promising results. Continued progress with these candidates brings us closer to a significant breakthrough in preventing and treating HSV infections.
- | HSV-2 vaccine (HSV529) / Sanofi, Merck (MSD)
Journal, IO biomarker: Expansion of the HSV-2-specific T cell repertoire in skin after immunotherapeutic HSV-2 vaccine. (Pubmed Central) - Aug 12, 2024
The skin in areas of HSV-2 reactivation possessed an oligoclonal TRB repertoire that was distinct from the circulation. Defining the influence of therapeutic vaccination on the HSV-2-specific TRB repertoire requires tissue-based evaluation.
- | HSV-2 vaccine (HSV529) / Sanofi, Merck (MSD), HSV2 vaccine (G103) / Merck (MSD), Sanofi, glucopyranosyl lipid A (G100) / Merck (MSD)
Journal: Nonclinical safety evaluation of two vaccine candidates for Herpes Simplex Virus type 2 to support combined administration in humans. (Pubmed Central) - Mar 21, 2023
Three repeated-dose toxicity studies, one in guinea pigs and two in rabbits, were conducted to assess systemic toxicity and local tolerance of HSV529, alone or adjuvanted with GLA-SE, or G103 containing GLA-SE. Data from these studies show that both vaccines are safe and well tolerated and support the ongoing HSV-2 clinical trial in which the two vaccine candidates will be given either sequentially or concomitantly to explore their potential synergistic and incremental effects.
- | HSV-2 vaccine (HSV529) / Sanofi, Merck (MSD)
Journal: Serum and Cervicovaginal Fluid Antibody Profiling in Herpes Simplex Virus (HSV) Seronegative Recipients of the HSV529 Vaccine. (Pubmed Central) - Feb 26, 2022
HSV2 gD antibody was detected in cervicovaginal fluid at about one-third the level of that in serum. A vaccine that induces potent serum antibodies transported to the genital tract might reduce HSV genital infection.
- || HSV-2 vaccine (HSV529) / Sanofi, Merck (MSD)
Clinical, P1 data, Journal: A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study of a Replication-Defective Herpes Simplex Virus 2 Vaccine, HSV529, in Adults With or Without HSV Infection. (Pubmed Central) - May 23, 2020
P1
HSV529 vaccine was safe and elicited neutralizing antibody and modest CD4+ T-cell responses in HSV seronegative vaccinees.Clinical Trials Registration. NCT01915212.
- | HSV-2 vaccine (HSV529) / Sanofi
Journal: Detection of residual proteins UL5 and UL29 using a targeted proteomics approach in HSV529, a replication deficient HSV-2 vaccine candidate. (Pubmed Central) - Aug 17, 2019
Results show that residual UL5 and UL29 proteins can be detected in the HSV529 candidate and that MRM analysis provides the appropriate sensitivity and specificity required for quantitation. The transition from nano-flow to ultra-performance driven chromatography was found to improve method robustness without compromising the sensitivity of the assay.
- || HSV-2 vaccine (HSV529) / Sanofi, Merck (MSD)
Trial completion: HSV529 Vaccine in HSV-2 Seropositive Adults (clinicaltrials.gov) - Jan 14, 2019
P1, N=10, Completed, Sponsor: Fred Hutchinson Cancer Research Center
The transition from nano-flow to ultra-performance driven chromatography was found to improve method robustness without compromising the sensitivity of the assay. Active, not recruiting --> Completed
- ||| HSV-2 vaccine (HSV529) / Sanofi, Merck (MSD)
Trial completion, Trial primary completion date: Study of the Safety of a Particular Herpes Vaccine in Adults With or Without Herpes Infection (clinicaltrials.gov) - Mar 8, 2017
P1, N=69, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Nov 2017 --> Mar 2017
- || HSV-2 vaccine (HSV529) / Sanofi, Merck (MSD)
Trial primary completion date: Study of the Safety of a Particular Herpes Vaccine in Adults With or Without Herpes Infection (clinicaltrials.gov) - Dec 5, 2016
P1, N=69, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed | Trial primary completion date: Nov 2017 --> Mar 2017 Trial primary completion date: Nov 2016 --> Nov 2017
- || HSV-2 vaccine (HSV529) / Sanofi, Merck (MSD)
Trial primary completion date: Study of the Safety of a Particular Herpes Vaccine in Adults With or Without Herpes Infection (clinicaltrials.gov) - May 5, 2016
P1, N=69, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: Nov 2016 --> Nov 2017 Trial primary completion date: Apr 2016 --> Nov 2016
- HSV-2 vaccine (HSV529) / Sanofi, Merck (MSD)
Enrollment closed: HSV529 Vaccine in HSV-2 Seropositive Adults (clinicaltrials.gov) - Mar 2, 2016
P1, N=10, Active, not recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Trial primary completion date: Apr 2016 --> Nov 2016 Recruiting --> Active, not recruiting
- HSV-2 vaccine (HSV529) / Sanofi, Merck (MSD)
Enrollment open: HSV529 Vaccine in HSV-2 Seropositive Adults (clinicaltrials.gov) - Nov 8, 2015
P1, N=10, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- HSV-2 vaccine (HSV529) / Sanofi, Merck (MSD)
New P1 trial: HSV529 Vaccine in HSV-2 Seropositive Adults (clinicaltrials.gov) - Oct 22, 2015
P1, N=10, Not yet recruiting, Sponsor: Fred Hutchinson Cancer Research Center
- HSV-2 vaccine (HSV529) / Sanofi, Merck (MSD)
Trial primary completion date: Study of the Safety of a Particular Herpes Vaccine in Adults With or Without Herpes Infection (clinicaltrials.gov) - Jul 16, 2015
P1, N=65, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting --> Recruiting Trial primary completion date: Jan 2030 --> May 2016
- || HSV-2 vaccine (HSV529) / Sanofi, Merck (MSD)
Enrollment closed: Study of the Safety of a Particular Herpes Vaccine in Adults With or Without Herpes Infection (clinicaltrials.gov) - May 29, 2015
P1, N=65, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: Jan 2030 --> May 2016 Enrolling by invitation --> Active, not recruiting
- || HSV-2 vaccine (HSV529) / Sanofi, Merck (MSD)
Enrollment status, Trial primary completion date: Study of the Safety of a Particular Herpes Vaccine in Adults With or Without Herpes Infection (clinicaltrials.gov) - May 4, 2015
P1, N=65, Enrolling by invitation, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Enrolling by invitation --> Active, not recruiting Recruiting --> Enrolling by invitation | Trial primary completion date: Oct 2016 --> Jan 2030
- HSV-2 vaccine (HSV529) / Sanofi, Merck (MSD)
Enrollment change: Study of the Safety of a Particular Herpes Vaccine in Adults With or Without Herpes Infection (clinicaltrials.gov) - Jun 17, 2014
P1, N=23, Enrolling by invitation, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Enrolling by invitation | Trial primary completion date: Oct 2016 --> Jan 2030 N=70 --> 23
- ||| HSV-2 vaccine (HSV529) / Sanofi, Merck (MSD)
New P1 trial: Study of the Safety of a Particular Herpes Vaccine in Adults With or Without Herpes Infection (clinicaltrials.gov) - Jul 31, 2013
P1, N=70, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)